Jeffrey J. Fessler

Overview

Jeffrey Fessler is a partner in the Corporate Practice Group in the firm's New York office. Jeffrey is Leader of the firm’s Capital Markets and Public Companies Team, as well as the firm’s Life Sciences Team.

“Jeffrey Fessler's client service and general level of service is very strong. His professional advice, covering a variety of matters, has been critical to the present and future success of the company.”
- Client Testimonial, Chambers USA 2024

Areas of Practice

Jeffrey is principally engaged in the practice of corporate and securities law. His practice is focused on the representation of public and private companies, principally in the biotechnology industry. Jeffrey has extensive experience representing investment banks and companies in public offerings and private placements as well as exchange listings and compliance. In addition, Jeffrey has been involved in a wide variety of corporate transactions, including mergers and acquisitions, joint ventures, proxy contests, restructurings and private equity and debt financings, as well as securities disclosure issues and corporate governance. In addition to the biotechnology industry, Jeffrey also represents companies in a variety of industries, including technology, telecommunications, broadcasting and healthcare.

Experience

Recent Representative Transactions

Represented Hepion Pharmaceuticals, Inc. in its $88.4 million follow-on offering
Represented Greenwich Life Sciences, Inc. in its $7.25 million initial public offering, as well as a subsequent $29.2 million follow-on offering
Represented Kiromic Biopharma, Inc. in its $15 million initial public offering
Represented BioXcel Therapeutics, Inc. in its $60 million initial public offering
Represented Aridis Pharmaceuticals, Inc. in its $26 million initial public offering
Represented Cardiff Oncology, Inc. in its $100 million follow-on public offering
Represented Synergy Pharmaceuticals, Inc. in its $125 million follow-on public offering
Represented Synergy Pharmaceuticals, Inc. in its $200 million Convertible Note Rule 144A offering
Represented Synergy Pharmaceuticals, Inc. in its $17.25 million public offering and uplisting to Nasdaq, as well as a subsequent $51 million public offering
Represented Northwest Biopharmaceuticals, Inc. in its $12 million public offering and uplisting to Nasdaq
Represented Sorrento Therapeutics, Inc. in its $34.6 million public offering and uplisting to Nasdaq, as well as a subsequent $28.8 million public offering
Represented Innovate Biopharmaceuticals, Inc. in its merger with RDD Pharmaceuticals, Ltd.